Lupin’s Somerset Manufacturing Plant Receives EIR from US FDA

The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)

Lupin ltd logo
article continues after this advertisement

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022.

The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

“We are very happy to have received the EIR from US FDA with satisfactory VAI classification for our Somerset facility. This is a significant milestone for our Somerset site, and an important step in our journey to build back our reputation as best in class in Quality and Compliance. We are committed to manufacture and supply products of the highest quality for the patients we serve,” said Vinita Gupta, CEO, Lupin.

Market Times

Shares of Lupin Ltd was last trading in BSE at ₹630.10 as compared to the previous close of ₹627.40. The total number of shares traded during the day was 14690 in over 702 trades.

The stock last hit in BSE,

  • Intraday High of ₹ 650.30
  • Intraday low of ₹ 622.65